CDKN2A, ARF and CDKN2B are cell cycle regulators and are plausible candidates for involvement in the pathogenesis of the diseases for which we found SNP associations with ANRIL. Mutations involving these genes are well documented in glioma [63], [64] and melanoma [49], [65], [66]. This evidence concerns the gene CDKN2B and central nervous system cancer.